Recon: Judge dismisses Chantix cancer risk suit; Janssen and Remix agree to $1B licensing deal for RNA reprograming tech

Recon

ReconJoanne S. Eglovitch

Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy